ClinicalTrials.Veeva

Menu

Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma (IFFaLCCO)

R

Rennes University Hospital

Status

Completed

Conditions

Ovarian Carcinoma

Study type

Observational

Funder types

Other

Identifiers

NCT02297958
2014-A01041-46

Details and patient eligibility

About

Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.

Enrollment

28 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Pre-Inclusion Criteria:

  • Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT)

Inclusion Criteria:

  • Pathological ovarian carcinoma diagnosed at pathological analysis after surgery.
  • Neo adjuvant chemotherapy

Exclusion Criteria:

  • no neo-adjuvant chemotherapy
  • no ovarian carcinoma at final pathological analysis
  • less than 18 years old.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems